<DOC>
	<DOCNO>NCT01091428</DOCNO>
	<brief_summary>This open-label , multicenter study nonrandomized Phase 1 portion open-label , randomize , Phase 2 portion evaluate MLN8237 combination weekly paclitaxel adult female patient advance breast cancer ( Phase 1 portion ) recurrent ovarian cancer ( Phase 1 Phase 2 portion ) .</brief_summary>
	<brief_title>MLN8237 Patients With Ovarian , Fallopian Tube Peritoneal Cancer Preceded Phase 1 Study MLN8237 Plus Paclitaxel Treatment Ovary Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : Female patient 18 year old Previously treat , metastatic locally recurrent malignancy 1 follow diagnosis , confirm histologically cytologically : adenocarcinoma breast ( Phase 1 ) , recurrent epithelial ovarian , fallopian tube , primary peritoneal carcinoma ( Phase 1 2 ) In Phase 1 portion study , patient breast cancer must receive treatment least 1 4 prior chemotherapy regimen include regimen receive neoadjuvant and/or adjuvant setting Patients breast cancer must measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 No antineoplastic therapy radiotherapy within 3 week enrollment ( 2 week regimens recovery expect within 7 14 day ) recover toxicity prior therapy ( except alopecia ) ; patient must recover treatmentrelated toxicity must evidence PD persistent disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow , liver renal function Postmenopausal least 1 year , OR Surgically sterile , OR If childbearing potential , agree 2 effective method nonhormonal contraception , agree completely abstain heterosexual intercourse Able provide write informed consent Willing comply schedule visit , treatment plan , laboratory test trial procedure Suitable venous access Specific Inclusion Criteria Patients Recurrent Ovarian , Fallopian Tube Peritoneal Cancer : Prior treatment must include platinum taxane ; recent treatment need platinumcontaining taxanecontaining regimen Disease must recur ≤ 12 month discontinuation platinum therapy Patients previously receive weekly taxane potentially eligible , provided progress therapy within 3 month complete therapy Patients platinumrefractory disease , define progression primary subsequent platinumbased therapy persistent radiographic disease primary subsequent platinumbased therapy , include Patients must measurable disease target lesion assessable disease ( define CA125 per protocol ) , disease progression per Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 modify Gynecologic Cancer Intergroup ( GCIG ) CA125 criterion Patients meet follow exclusion criterion enrol study : Prior treatment Aurora Atargeted agent ( include MLN8237 ) Treatment clinically significant enzyme inducer within 14 day prior first dose MLN8237 study Treatment 4 cytotoxic chemotherapy regimens metastatic setting ; prior therapy include 2 prior taxanecontaining regimen Known hypersensitivity Cremophor® EL , paclitaxel component Prior history ≥ Grade 2 neurotoxicity toxicity require discontinuation taxane chemotherapy resolve ≤ Grade 1 Comorbid unresolved toxicity would preclude administration weekly paclitaxel Primary central nervous system malignancy carcinomatous meningitis Symptomatic brain metastasis Inability swallow oral medication maintain fast History hemorrhagic thrombotic cerebrovascular event past 12 month Surgery within 3 week study enrollment fully recover Diagnosis treatment another malignancy within 2 year precede first dose MLN8237 evidence residual disease except nonmelanoma skin cancer situ malignancy completely resect Pregnant lactate Serious illness could interfere protocol completion Investigational treatment 21 day prior first dose MLN8237 Prior allogeneic bone marrow organ transplantation Infection require systemic antibiotic therapy within 14 day prior first dose MLN8237 Known history human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C Radiotherapy &gt; 25 % bone marrow whole pelvic radiotherapy Requirement constant administration proton pump inhibitor , H2 antagonist , pancreatic enzyme . Intermittent us antacid H2 antagonist allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>RECIST : Response Evaluation Criteria Solid Tumors</keyword>
	<keyword>OC : Ovarian Cancer</keyword>
	<keyword>GCIG : Gynecologic Cancer Intergroup</keyword>
	<keyword>Breast carcinoma ( Phase 1 )</keyword>
</DOC>